BioSpace News Archive

BrainStorm Enrolls First Patients In Phase III Trial Of NurOwn In ALS

BrainStorm Cell Therapeutics today announced that the first patients have been enrolled in the Phase 3 clinical trial of NurOwn for the treatment of amyotrophic lateral sclerosis (ALS) at the Massachusetts General Hospital and UC Irvine Medical Center in California.

October 16, 2017

·

5 min read

Biotech Bay

Genentech To Present New OCREVUS (Ocrelizumab) Efficacy & Safety Data In Relapsing And Primary Progressive Forms Of Multiple Sclerosis At ECTRIMS

Genentech announced today that new data on OCREVUS (ocrelizumab) in people with relapsing and primary progressive forms of multiple sclerosis (MS) will be presented during the 7th Joint European Committee for Treatment and Research in Multiple Sclerosis.

October 16, 2017

·

15 min read

GenSight Biologics To Present Data On GS010 And GS030 At The 2017 Congress Of The European Society Of Gene & Cell Therapy

GenSight Biologics today announced multiple data presentations at the Congress of the European Society of Gene and Cell Therapy (ESGCT) in Berlin, Germany, October 17-20, 2017.

October 16, 2017

·

5 min read

Lone Star Bio

Renflexis Is Latest Addition To Therapeutic Drug Monitoring By Miraca Life Sciences

Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand in clinical pathology: its InformTx therapeutic drug monitoring (TDM) has begun the validation process for Renflexis (infliximab-abda), a biosimilar of Remicade (infliximab).

October 16, 2017

·

3 min read

Drug Development

Chi-Med Reports Preliminary Phase II Data On Fruquintinib Combination In First-Line Lung Cancer

Hutchison China MediTech Limited today reported preliminary clinical activity, safety, and tolerability data of fruquintinib.

October 16, 2017

·

6 min read

Genetown

Takeda Presents Updated Results From Pivotal Phase II ALTA Trial Of ALUNBRIGTM (Brigatinib) In ALK-Positive Non-Small Cell Lung Cancer

Takeda Pharmaceutical Company Limited today announced that data from the pivotal Phase 2 ALTA will be presented in an oral session at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) on Monday, October 16, 4:30 p.m.- 4:40 p.m. JST.

October 16, 2017

·

16 min read

Drug Development

Bristol-Myers Squibb Release: Opdivo Alone Or Combined With Yervoy In Exploratory Analysis From Phase I/II Study Checkmate -032

Bristol-Myers Squibb Company today announced data evaluating Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab) from the Phase 1/2 CheckMate -032 trial.

October 16, 2017

·

29 min read

ChemPass And LifeArc Report Positive Results In The Validation of ChemPass Technology In Medicinal Chemistry Programs

ChemPass announced today that they have successfully completed the first phase of their evaluation of ChemPass’ technology for its ability to support LifeArc’s medicinal chemistry programs.

October 16, 2017

·

2 min read

Business

QIAGEN N.V. To Report Third Quarter And First Nine Months Of 2017 Results

QIAGEN N.V. plans as previously announced to release its report on results for the third quarter and first nine months of 2017 on Monday, November 6 at approximately 22:00 Central European Time (CET) / 16:00 Eastern Time (EDT).

October 16, 2017

·

2 min read

Drug Development

Eli Lilly Release: Rapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown To Benefit In New CYRAMZA (Ramucirumab) Phase III Subgroup Analysis

New subgroup analysis from Eli Lilly’s Phase 3 REVEL trial of CYRAMZA (ramucirumab) in advanced non-small cell lung cancer (NSCLC) was presented today at the 18th World Conference on Lung Cancer (WCLC).

October 16, 2017

·

29 min read